
Industry symposia

Our industry supporters will once again be offering you an outstanding programme of sessions to complement your attendance at Rheumatology 2010. These symposia, featuring exciting speakers and innovative formats continue to be an essential part of the delegate experience.
Currently booked to run sessions are:
Provisional programmes (last updated 11 March 2010):
Tuesday 20 April 2010 19.30 - 21.00
GSK

Targeting BLyS Inhibition for Systemic Lupus Erythematosus
Chairman’s Introduction
Prof Graham Hughes
A brief overview of the history of Lupus
Prof Graham Hughes
Unmet Needs in Lupus: A Patient and Physician Perspective
Prof Caroline Gordon
Rationale for BLySInhibitors in Lupus
Dr MuntherKhamashta
Clinical Effect of BLySInhibition: evidence from clinical trials
Prof David D'Cruz
Wednesday 21 April 2010 18.00 - 19.30
Abbott

What a difference a change can make: practical solutions for the clinic
How we need to evolve our service to meet future needs: a clinical director’s perspective
Prof Paul Emery, arc Professor of Rheumatology
How we improved patient care without a change in resources: a clinician’s perspective
Dr Andrew Östör, Cambridge
The impact of practical changes on patients’ lives: patients’ perspectives
Mrs Tricia Cornell, Poole
TICORA in clinical practice: the inside story
Dr Duncan Porter, Glasgow
Interactive panel discussion
Roche (Roactemra)

Inflammatory Issues.
Your chance to participate in a satellite symposium with a difference.
Join an expert faculty to debate current ‘inflammatory issues’ in RA.
Introduction
Prof DGI Scott, Norfolk and Norwich University Hospital
New biological treatments for RA
Prof Peter Taylor, Imperial College, London
Peer-to-Peer group debates
Audience debates issues in small groups
Feedback, discussion and closing remarks
Facilitated by Prof DGI Scott
The debates.
New biological drugs - optimising uptake at the front end of the treatment algorithm
o Prof Peter Taylor, Imperial College, London
o Dr Maya Buch, University of Leeds
Early RA intervention to prevent radiographic progression
o Prof Philip Conaghan, University of Leeds
o Dr Allister Taggart, City Hospital, Belfast
The impact of new biologicals - how should new MOA be utilised?
o Dr Ernest Choy, King’s College Hospital, London
o Prof John Isaacs, University of Newcastle upon Tyne
CV risk and RA
o Prof George Kitas, Russell’s Hall Hospital, Dudley
The perceived risks of biological treatments in RA
o Dr Lesley Kay, Freeman Hospital, Newcastle upon Tyne
o Prof DGI Scott, Norfolk and Norwich University Hospital
How to expand access to biologics and move RA up the political agenda
o Dr Andrew Bamji, Queen Mary's Hospital, Sidcup
All aspects of this promotional symposium are sponsored by Roche Products Ltd and Chugai Pharma UK Ltd
Thursday 22 April 2010 18.00 - 19.30
Roche (Mabthera)
To B or not to B: what is YOUR question?
Join a panel of experts from the field of rheumatology including Professor John Isaacs, Professor Andrea Rubbert, Dr Tom Sheeran and Patricia Cornell, along with GP and media medic Dr Dawn Harper who will be facilitating the session, at To B or not to B: what is YOUR question? a symposium session with a difference. With no presentations and no set agenda, To B or not to B: what is YOUR question? offers you the chance to choose the topics and ask the questions.
Roche financially supports every aspect of the To B or not to B: what is YOUR question? symposium and has chosen and reimbursed the faculty for their participation and all associated expenses. This is a promotional meeting.
UCB Pharmaceuticals

A patient-focused approach to the management of rheumatoid arthritis
Welcome
Prof Peter C Taylor
A patient-led model of care: What is the RA patient really looking for?
Mrs Ailsa Bosworth, National Rheumatoid Arthritis Society
Meeting the needs of RA patients in the ‘real-world’
Dr Tony Hammond
Spotlight on RA management: The commissioning perspective
Mr Craig Black
Treating RA: The benefits and challenges of new and emerging treatments
Prof Peter C Taylor
Case study and discussion
Led by Prof Peter C Taylor
Summary and close
Prof Peter C Taylor
Friday 23 April 2010 07.30 - 09.00
Actelion
Friday 23 April 2010 07.30 - 09.00
Friday 23 April 2010 07.30 - 09.00
Question Time: Rapid referral vs effective local care in PAH
What is best for the patient?
Meeting Chair: Jon Snow, Journalist, TV & Radio presenter
Meeting Co-Chair: Dr David Kiely, Consultant Physician in Respiratory and General Medicine,
Royal Hallamshire Hospital, Sheffield
Panel members:
Prof Neil McHugh, Consultant Rheumatologist, Royal National Hospital for Rheumatic diseases, Bath
Dr Frances Hall, Consultant Rheumatologist, Addenbrooke’s Hospital, Cambridge
Dr Gerry Coghlan, Consultant in Cardiology, Royal Free Hospital, London
Welcome breakfast
Welcome and introduction of the panel Jon Snow
Presentation: Managing an aggressive disease Dr David Kiely
Question time:
Panel to discuss and debate the optimal management for PAH associated with systemic sclerosis
• Identification of patients: What is the value of identifying asymptomatic patients?
• What do specialist PAH centres offer vs local care?
Audience Q & A
What is best for the patient?
Summary and close
Amgen

A New Force against Fracture
Welcome and introduction - Prof Jon Tobias
· Symposium objectives
A focus on fractures - Dr Gavin Clunie
· Rationale for an FLS
· Results and observations made in a real world FLS
Breaking down barriers to adherence - Rob Horne
· Latest results from the UK GPRD looking at adherence in osteoporosis
· Myths behind non-adherence
· Intentional non-adherence
· Unintentional non-adherence
A new force against fracture - Prof David Reid
· RANK/RANKL/OPG pathway
· FREEDOM results
· DECIDE and STAND
· Tolerability and administration
Realising clinical data in the real world - TBC
· The role of the clinical lead in securing funding for services and new medicines
· Key points to consider for denosumab
· Case example
Q & A - Prof Jon Tobias